替诺福韦的肾毒性及其遗传药理学研究状况  

Rsearch status of tenofovir on renal toxicity and pharmacogenetics

作　　者：喻婉莹[1,2] 黄洁[2] 阳国平[1,2] 

机构地区：[1]中南大学药学院,长沙410013 [2]中南大学湘雅三医院,长沙410013

出　　处：《中国临床药理学杂志》2015年第14期1459-1461,1465,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家重大新药创制科技重大专项基金资助项目(2012ZX09303014-001);Supported by International S&T Cooperation Program of China(2014DFA30900)

摘　　要：替诺福韦(TFV)是一类抑制HIV-1反转录酶的腺苷磷酸无环核苷类似物,因其高有效性、低毒性及其每天只用服用一次的便利而被广泛使用。然而,该药可引起肾功能损伤。肾功能损伤存在着较高的个体差异,因此越来越多的研究关注于替诺福韦引起的肾损伤与遗传因素的相关性。本文对替诺福韦的肾毒性的相关遗传因素进行综述。Tenofovir（ TFV） is a class of inhibiting HIV-1 reverse transcriptase,adenosine phosphate acyclic nucleoside analogs. Because of its high effectiveness,low toxicity and only be taken once per day,it is widely used nowadays. However,it was reported that the drug can cause kidney damage. Since there is a high individual difference of renal impairment,more and more researches focus on the association of renal injury which caused by TFV and genetic factors. The nephrotoxicity of tenofovir and the genetic factors which may increase renal tubular disease are reviewed in this paper.

关 键 词：替诺福韦 肾毒性 遗传因素 

分 类 号：R978.7[医药卫生—药品]